How Terlivaz Treats Hepatorenal Syndrome (HRS)
Terlivaz (terlipressin), approved by the FDA in 2022, treats adults with hepatorenal syndrome (HRS) type 1, a rapidly progressive kidney failure triggered by advanced liver disease like cirrhosis. HRS occurs when severe liver dysfunction causes splanchnic vasodilation, leading to reduced effective blood volume, intense renal vasoconstriction, low kidney blood flow, and acute kidney injury.[1]
Terlivaz works as a vasopressin V1A receptor agonist. It constricts smooth muscle in the splanchnic arteries, countering vasodilation and redirecting blood flow to the kidneys. This raises mean arterial pressure (a key trial endpoint), improves renal perfusion, and boosts serum creatinine clearance, halting or reversing HRS progression.[1][2]
In the phase 3 CONFIRM trial, 29-36% of Terlivaz patients achieved verified HRS reversal (two consecutive creatinine ≤1.5 mg/dL for ≥2 days) versus 16% on placebo, with effects seen within days of IV administration (starting at 0.85 mg every 6 hours, titrated up to 2 mg).[2]
How Is Terlivaz Administered for HRS?
Terlivaz is given intravenously every 6 hours, typically in a hospital setting for close monitoring. Dosing starts low and increases based on blood pressure and sodium response, up to 14 days. It's not for outpatient use due to risks like ischemia.[1]
What Happens If Treatment Fails?
If no response after 4 days (creatinine drop <30%), guidelines recommend stopping Terlivaz and considering alternatives like albumin plus vasoconstrictors (e.g., norepinephrine) or liver transplant evaluation. HRS has high mortality without intervention.[3]
Common Side Effects and Risks
Terlivaz carries a boxed warning for serious respiratory failure. Other risks include abdominal pain, nausea, hyponatremia, and ischemia (e.g., in limbs or heart). Patients with septic shock or acute coronary issues are excluded. Monitoring includes daily labs and blood pressure.[1][2]
How Does Terlivaz Compare to Older HRS Treatments?
Unlike off-label midodrine/octreotide (less effective in trials), Terlivaz showed superior HRS reversal rates. It's the first U.S.-approved HRS-specific drug, though albumin is still paired routinely to expand blood volume. In Europe, terlipressin has been used longer but faced similar safety scrutiny.[3]
Who Makes Terlivaz and What's the Cost?
Mallinckrodt manufactures Terlivaz. List price is about $4,500 per day (variable by dose), often covered by insurance for HRS but with prior authorization. No U.S. patents listed as expired on DrugPatentWatch.com; exclusivity tied to orphan drug status.[4][1]
Sources
[1]: Terlivaz Prescribing Information (FDA)
[2]: CONFIRM Trial (NEJM)
[3]: AASLD HRS Guidelines
[4]: DrugPatentWatch.com - Terlivaz